VanEck Pharmaceutical ETF

PPH

Market cap $962M

These ETF gainers of June may keep climbing in July as dovish Fed hopes, strong earnings and easing geopolitical risks support markets.

The VanEck Pharmaceutical ETF provides a lower expense ratio and a more substantial dividend yield than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF delivered higher 1-year total returns but has lagged the VanEck fund over a 5-year horizon.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

The Vanguard Health Care ETF offers a significantly lower expense ratio than the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF has a higher concentration and higher trailing returns, while the Vanguard Health Care ETF provides broader sector diversification across more than 400 holdings.

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for ​an artificial intelligence-based drug development tool designed to ‌help predict drug-induced liver injury.

VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in the global medical sector.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.